Exclusive License AgreementExclusive License Agreement • April 4th, 2024 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), entered into as of March 31, 2023 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a company incorporated under the laws of the State of Delaware (“Takeda”), and Innate Pharma S.A., a company organized and existing under the laws of the country of France (“Innate”). Innate and Takeda are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
